Valerian for anxiety disorders

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Miyasaka, Lincoln Sakiara ^a   Atallah, A N ^b   Soares, B G O ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; PLACEBO; VALERIAN;

AGORAPHOBIA; ANXIETY DISORDER; ANXIETY NEUROSIS; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENERALIZED ANXIETY DISORDER; HUMAN; MEDLINE; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; RATING SCALE; REVIEW; SCORING SYSTEM; SOCIAL PHOBIA; SOMNOLENCE; SYSTEMATIC REVIEW; THERAPY DELAY;

EID: 42749103647     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004515.pub2     Document Type: Review

References (39)

1. Andreatini R, Sartori VA, Seabra MLV, Leite JR. Effect of valepotriates (valerian extract) in Generalised Anxiety Disorder: a randomised placebo-controlled pilot study. Phytotherapy Research 2002;16:650-4.
2. Bourin M, Bougerol T, Guitton B, Broutin E. A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. Fundamental and Clinical Pharmacology 1997;11(2):127-32.
3. * Cerny A, Schmid K. Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind placebo controlled multicentre study). Fitoterapia 1999;70:221-8.
4. * Delsignore R, Orlando S, Costi D, Baroni MC, Butturini U. Clinical comparative evaluation of a stabilized valeriana extract and placebo [Avaliação clinica comparativa com placebo de um extrato estabilizado de valeriana]. A Folha Medica 1992;104(5):191-196.
5. * Maisenbacher J, Podzuweit H. Valerian and Melissa - Mild Psychopharmaceuticals. Therapiewoche 1992;42(37):2140-2144.
6. * McCutcheon LE. Treatment of anxiety with a homeopathic remedy. Journal of Applied Nutrition 1996;48(1,2):1-5.
7. Panijel M. Treatment of moderately severe anxiety states. Therapiewoche 1985;41:4659-68.
8. * Rabezzana G. Tratamento dei disturbi d'ansia de grado lieve emedio con prodotti a base naturale: valutazione dell"efficacia e tollerabilità del Sedatol. Riv It Biol Med 1995;15:126-133.
9. Almeida-Filho N, Mari JJ, Coutinho E, Franca JF, Fernandes J, Andreoli SB, et al. Brazilian multicentric study of psychiatricmorbidity: Methodological features and prevalence estimates. British Journal of Psychiatry 1997;171:524-9.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-III-R). 3rd Edition. Washington DC: American Psychiatric Association, 1987.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
12. British Herbal Medicine Association. British Herbal Compendium Vol. 1. Bournemouth: British Herbal Medicine Association, 1992.
13. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: Results of the Netherland Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry & Psychiatric Epidemiology 1998;33(12):587-95.
14. Borkovec TD, Mathews AM, Chambers AM, Ebrahimi S, Lytle R, Nelson R, et al. The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder. Journal of Consulting & Clinical Psychology 1987;55(6):883-8.
15. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. Journal of Consulting & Clinical Psychology 1993;61(4):611-9.
16. Clarke M, Oxman AD. Cochrane Collaboration Handbook. Oxford: Update Software, 2000.
17. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000;33(2):47-53.
18. Gould RA, Otto MW, Pollack MH, Yap L. Cognitive behavioural and pharmacological treatment of generalized anxiety disorders: Preliminary meta-analysis. Behavior Therapy 1997;28(2):285-305.
19. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
20. Hendriks H, Bos R, Allersma DP, Malingre TM, Koster AS. Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Medica 1981;42(1):62-8.
21. Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder [Psychotherapies for generalized anxiety disorder]. In: Cochrane Library, 4, 2006. Oxford: Update Software.
22. Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
23. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12 month prevalence of DSM III-R psychiatric disorders in United States. Archives of General Psychiatry 1994;51(1):8-19.
24. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Medica 1985;51(2):144-8.
25. Mayer B, Springer E. Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol [Psyschoexperimentelle untersuchungen zur wirking einer Valepotriatkombination sowie zur Kombinierten wirkung von Valtratum und Alkohol]. Arzneimittel-Forschung 1974;24(12):2066-70.
26. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. American Journal of Psychiatry 2000;157(6):669-82.
27. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P. In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 1993;64(4):291-300.
28. Petkov VD, Manolov PN, Marekov NL, Popov SS, Handjieva NB. Pharmacological studies on a mixture of valepotrietes isolated from Valeriana officinalis. Doklady Bolgarskoi Akademii Nauk 1974;27:1007-10.
29. Pittler MH, Ernst E. Kava extract for treating anxiety. In: Cochrane Library, 3, 2002. Oxford: Update Software.
30. Priest RG, Montgomery SA, Priest RG, Montgomery SA. Benzodiazepines and dependance: a college statement. Bulletin of the Royal College of Psychiatrists 1988;12:107-08.
31. Schmidt-Voigt J. Treatment of nervous sleep disorders and unrest with a sedative of purely vegetable origin [Die Behandlung nervoser schfstorungen und innerer unruhe mit einem rein pflanzlichen sedativum]. Therapiewoche 1986;36(7):663-7.
32. Schulz KF, Chalmers I, Haves RJ, Altman DG. Empirical evidence of bias: Dimension of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
33. Stevinson C, Ernst E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Medicine 2000;1(2):91-9.
34. Taylor CB. In: Agras WS editor(s). Relaxation training and related techniques in behavioural modifications: Principles and clinical applications. Boston, MA: Little Brown, 1978.
35. Taylor CB, Arnow B. The nature and the treatment of anxiety disorders. New York, NY: Free Press, 1988.
36. Von Eickstedt KW, Rahman S. Psychopharmacologic effect of valepotriates [Psychopharmakologische wirkungen von valepotriaten]. Arzneimittel- Forschung 1969;19(3):316-9.
37. Vorbach EU, Gortelmeyer R, Bruning J. Therapy of insomnia. The efficacy and tolerability of valerian [Therapie von Insomnien. Wirksamkeit und Vertraglichkeit eines Baldrianpraparats]. Psychopharmakotherapie 1996;3(3):109-15.
38. Walley EJ, Beebe DK, Clark JL. Management of common anxiety disorders. American Family Physician 1994;50(8):1745-53.
39. Ziegler G, Ploch M, Miettinen-Baumann A, Collet W. Efficacy and tolerability of valerian extract LI 156 compared with oxazepamin the treatment of non-organic insomnia, a randomized double blind comparative clinical study. European Journal of Medical Research 2002;7(11):480-6.